<DOC>
	<DOCNO>NCT01862315</DOCNO>
	<brief_summary>The purpose study use , liver pump treatment systemic chemotherapy , assess effect type treatment patient tumor . Liver pump treatment use metal pump surgically place abdomen give chemotherapy directly liver . Systemic chemotherapy give chemotherapy vein [ intravenously ( IV ) ] treat whole body . This type treatment do show people pump systemic chemotherapy improve result . The investigator hope combination treatment improve response chemotherapy reduces spread disease . Another purpose study learn clinical importance specific type MRI scan . The investigator would like see type MRI help predict response treatment see could help physician treatment plan . These scan do specific time point . The last purpose study learn tumor interacts chemotherapy . This do biopsy take surgery blood draw specific time point . Permission patient enter study obtain take normal tumor liver biopsy time surgery . These sample voluntary optional .</brief_summary>
	<brief_title>Hepatic Arterial Infusion ( HAI ) With Floxuridine ( FUDR ) Dexamethasone ( Dex ) Combined With Systemic Gemcitabine Oxaliplatin Patients With Unresectable Intrahepatic Cholangiocarcinoma ( ICC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Age ≥ 21 year Histologically confirm intrahepatic cholangiocarcinoma ( also variously report peripheral cholangiocarcinoma , cholangiolar carcinoma cholangiocellular carcinoma ) ( ICC ) . Confirmation diagnosis MSKCC enrol institution must obtain prior initiation protocol therapy . Clinical radiographic evidence metastatic disease regional lymph node allow , provide amenable resection . Radiographically measurable disease . Measurable disease define disease assess 2dimensional measurement crosssectional imaging . Minimum lesion size 2cm great diameter per RECIST criterion . Disease must consider unresectable time preoperative evaluation . Presence le 70 % liver involvement cancer . Patients may fail ablative therapy Patient previously treat systemic chemotherapy eligible KPS ≥ 60 % consider candidate general anesthesia , abdominal exploration hepatic artery pump placement Patients chronic hepatitis and/or cirrhosis eligible , must ChildPugh class A Patients must able read , understand sign inform consent WBC ≥ 2,000 cells/mm3 Platelet count ≥ 75,000/mm3 Creatinine ≤ 1.8 mg/dl Total bilirubin &lt; 1.5 mg/dl Presence distant metastatic disease . Patients undergo radiographic evaluation exclude possibility distant metastatic disease . For patient undergone pre postoperative biopsy definitively diagnose ICC , diagnostic study may modify discretion MSKCC Principal Investigator . Clinical radiographic evidence metastatic disease regional lymph node allow , provide amenable resection . Prior treatment FUDR Prior external beam radiation therapy liver Diagnosis sclerosing cholangitis Clinical evidence portal hypertension ( ascites , gastroesophageal varix , portal vein thrombosis ) surgically relate ascites exclude patient ) Active infection Pregnant lactate woman History malignancy within past 3 year ( except nonmelanoma skin cancer ) Life expectancy le 12 week Inability comply study and/or followup procedure History peripheral neuropathy ( Note : apply Cohort 3 )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatic Arterial Infusion ( HAI )</keyword>
	<keyword>Floxuridine ( FUDR )</keyword>
	<keyword>Dexamethasone ( DEX )</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>13-066</keyword>
</DOC>